Immunology and Bi...
Follow
Find
4.5K views | +3 today
Scooped by Gilbert Faure au nom de l'ASSIM
onto Immunology and Biotherapies
Scoop.it!

Cellular & Molecular Immunology - Attenuated Listeria ... - Rss - Nature

Cellular and Molecular Immunology aims to report the dynamic progress being made in China and abroad in immunological research, and welcomes high-quality Research Articles, Reviews and Brief Reports across a broad ...
more...
No comment yet.
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert Faure au nom de l'ASSIM's insight:

We choose Scoop.it as the best curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Generation and in vivo evaluation of IL10-treated dendritic cells in a ... - Nature.com

Generation and in vivo evaluation of IL10-treated dendritic cells in a ... - Nature.com | Immunology and Biotherapies | Scoop.it
Generation and in vivo evaluation of IL10-treated dendritic cells in a ...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Medical Biopathology and Laboratory Medicine
Scoop.it!

Personalized Medicine Market Trends, Part Two - Genetic Engineering News

Personalized Medicine Market Trends, Part Two - Genetic Engineering News | Immunology and Biotherapies | Scoop.it
Genetic Engineering News Personalized Medicine Market Trends, Part Two Genetic Engineering News Even though the concept of personalized medicine is relatively straightforward, its implementation in clinical practice has been elusive due to a number...
more...
Gilbert Faure au nom de l'ASSIM's curator insight, July 25, 6:50 AM

not so many people convinced, unfortunately

Gilbert Faure au nom de l'ASSIM's curator insight, July 25, 6:57 AM

liquid biopsies at the end of PPT...

no other biological fluids (ascites, CSF...) detailed too early?

Scooped by Gilbert Faure au nom de l'ASSIM from Adoptive T Cell Immunotherapy
Scoop.it!

Invariant NKT cells with chimeric antigen receptor pro... [Blood. 2014] - PubMed - NCBI

in mice

.... proposed that CAR expression in Vα24-invariant NKT cells (NKTs) can build upon the natural antitumor properties of these cells while their restriction by monomorphic CD1d limits toxicity. Primary human NKTs were engineered to express a CAR against the GD2 ganglioside (CAR.GD2), which is highly expressed by neuroblastoma.


Via Julien Valton
Gilbert Faure au nom de l'ASSIM's insight:

Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.

more...
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

The glucocorticoid receptor 1A3 promoter correlates with high sensitivity to ... - Nature.com

The glucocorticoid receptor 1A3 promoter correlates with high sensitivity to ...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

New Monoclonal Antibody Developed That Can Target Proteins Inside Cancer Cells

New Monoclonal Antibody Developed That Can Target Proteins Inside Cancer Cells | Immunology and Biotherapies | Scoop.it
Scientists from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics have collaborated to create the new human monoclonal antibody, which targets a protein associated with many types of cancer and is of great interest to cancer researchers.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Dendritic Cell-Derived Exosomes as Immunotherapies in the Fight against Cancer [BRIEF REVIEWS]

Exosomes are nanometric membrane vesicles of late endosomal origin released by most, if not all, cell types as a means of sophisticated intercellular communication.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Process Challenges of Antibody–Drug Conjugates | BioProcess International

Process Challenges of Antibody–Drug Conjugates | BioProcess International | Immunology and Biotherapies | Scoop.it
ADCs show promise despite a number of challenges. Read Dr. Wooge’s take in this @BioProcessIntl piece: http://t.co/l11P0Wbm7E
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Directed Evolution of an LBP/CD14 Inhibitory Peptide and Its Anti-Endotoxin Activity

by Li Fang, Zhi Xu, Guan-song Wang, Fu-yun Ji, Chun-xia Mei, Juan Liu, Guo-ming Wu
Background LPS-binding protein (LBP) and its ligand CD14 are located upstream of the signaling pathway for LPS-induced inflammation.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Cure for cancer - the other truth: Antibody Drug Conjugates (ADCs) a new type of compound that potentially cures end-stage terminal patients

Cure for cancer - the other truth: Antibody Drug Conjugates (ADCs) a new type of compound that potentially cures end-stage terminal patients | Immunology and Biotherapies | Scoop.it
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Prima Receives US Patent Grant for CVac - Wall Street Journal

Prima Receives US Patent Grant for CVac - Wall Street Journal | Immunology and Biotherapies | Scoop.it
Prima Receives US Patent Grant for CVac Wall Street Journal The patent grant protects the method of composition and the method of use of CVac, which is formulated in a patient's own dendritic cells and then reinjected back into the patient to...
more...
Société Francaise d'Immunologie's curator insight, July 20, 5:22 AM

CVac production involves formulating the treatment using a patient’s own dendritic cells and then reinjecting it into the patient to generate a cytotoxic T cell response against mucin 1, an antigen found on the surface of cancer cells. - See more at: http://lifescientist.com.au/content/health-medical/article/prima-picks-up-us-patent-for-cancer-treatment-cvac-998649086#sthash.ZmfCTaI6.dpuf

in ovarian cancer

Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Immunotherapy top 5 indications in clinical trials

Immunotherapy top 5 indications in clinical trials | Immunology and Biotherapies | Scoop.it

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, July 19, 5:11 PM

The top 5 cancer types listed by the number of immunotherapy clinical trials, derived from ClinTrials.gov

 

Neoplasm Glandular/Epithelial     228

Neoplasm Nerves                                203

Carcinoma                                              192

Melanoma                                               127

Leukemia                                                  108

 

 

Gilbert Faure au nom de l'ASSIM's comment, July 20, 3:42 AM
nice synthesis! I had recently a similar idea to write "capsules" on topics of interest
Krishan Maggon 's comment, July 21, 10:17 AM
Very good idea, i wish there was a way to collaborate and place for collaborative efforts. thanks and best regards
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Introduction: Immunotherapy Research Milestones - OncLive

Introduction: Immunotherapy Research Milestones - OncLive | Immunology and Biotherapies | Scoop.it
Introduction: Immunotherapy Research Milestones
OncLive
Moderator Louis M. Weiner, MD, introduces a panel discussion focused on monoclonal antibody-based immunotherapy for patients with various types of cancer.

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

New checkpoint inhibitor mabs : TIM3 and LAG3

TIM-3, or T-cell immunoglobulin and mucin domain-3, functions as a pattern recognition receptor that dampens the anti-tumor immune response. Anti-TIM-3 antibodies have shown preclinical anti-tumor activity and may enhance anti-tumor immunity in combination with an anti-PD-1 agent or other immune modulating molecules.

 

LAG-3, or lymphocyte activation gene-3, is a negative regulator of T-cell activity. Preclinical studies have demonstrated anti-tumor activity by blocking LAG-3 and PD-1 in tumor models, and LAG-3 IgG fusion protein has demonstrated promising results in clinical trials for various solid tumors.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, Today, 1:08 PM

Besides CTLA4, PD1 and PDL1, 2 new checkpoint inhibitor mabs targeting  TIM3 and LAG3 are in early stages of development.

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Defining Critical Quality Attributes for Monoclonal Antibody Therapeutic Products - An approach for establishing the CQAs of a mAb product by evaluating impact and uncertainty during risk assessment

Defining Critical Quality Attributes for Monoclonal Antibody Therapeutic Products - An approach for establishing the CQAs of a mAb product by evaluating impact and uncertainty during risk assessment | Immunology and Biotherapies | Scoop.it
Establishing the CQAs of a mAb product by evaluating impact and uncertainty during risk assessment.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2013
Scoop.it!

Soliris® (eculizumab) Sales to top $ 2 billion in 2014. Alexion 2Q2014

Soliris® (eculizumab) Sales to top $ 2 billion in 2014. Alexion 2Q2014 | Immunology and Biotherapies | Scoop.it
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the three and six months ended June 30, 2014. The Company reported net product sales of Soliris® (eculizumab) of $512.5 million in the second quarter of 2014, an increase of 38 percent from the same period in 2013.

Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:

impressive

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Allergy and Clinical Immunology
Scoop.it!

Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab

Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab | Immunology and Biotherapies | Scoop.it
Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test (New article: Severe hypersensitivity reactions to cetuximab #LibertasAcademica #anaphylaxis
Gilbert Faure au nom de l'ASSIM's insight:

pour plus d'informations récentes sur le cituximab dans ce sujet

http://www.scoop.it/t/immunology-and-biotherapies?q=cetuximab

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Rapid Generation of Virus-Specific T Cells Helps Fight Off Infection in ... - Cancer Network

Rapid Generation of Virus-Specific T Cells Helps Fight Off Infection in ... - Cancer Network | Immunology and Biotherapies | Scoop.it
Rapid Generation of Virus-Specific T Cells Helps Fight Off Infection in ...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Tumor Infiltrating Lymphocytes (TIL) : Lion Biotechnologies

Tumor Infiltrating Lymphocytes (TIL) : Lion Biotechnologies | Immunology and Biotherapies | Scoop.it

TIL Technology 

In the early stages of cancer, special immune cells known as tumor infiltrating lymphocytes (TILs) migrate to the tumor and launch an attack.  However, this effect is usually short-lived because cancer adapts to evade immune detection and suppress immune response. Lion’s TIL technology is designed to overcome the immunosuppressive effects of cancer, while leveraging and enhancing the power of TILs to treat, and potentially cure, all solid tumors.

Our TIL technology has demonstrated robust efficacy in Phase 2 clinical trials, indicating objective response rates of 49% in Stage 4 metastatic melanoma.  Based on an adoptive cell therapy regimen developed by Steven A. Rosenberg, MD, chief of surgery at National Cancer Institute (NCI), it is currently in use as a physician-sponsored investigational treatment for Stage IV metastatic melanoma at NCI, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute.


Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:

TIL back on stage? they are not in memories of most students

more...
Krishan Maggon 's curator insight, July 23, 10:13 PM

Lion Biotech TIL is in Phase II trials in advanced metastatic melanoma and in Phase I trials in combination with BRAF inhibitor Zelboraf (vemurafenib, Roche) and in another Phase I with Yervoy (Ipilimumab, BMS). all trials are with NCI.

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

MRC Technology Announces Humanization of Anti-Tau Monoclonal Antibody for Alzheimer’s Disease Therapy - MRC Technology

MRC Technology Announces Humanization of Anti-Tau Monoclonal Antibody for Alzheimer’s Disease Therapy - MRC Technology | Immunology and Biotherapies | Scoop.it
Antibody inhibits Tau aggregation involved in the pathology of Alzheimer’s and other neurodegenerative diseases (We've humanized an anti-Tau antibody for Alzheimer's disease therapy on behalf of AXON Neuroscience SE
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Differential Modulation of Donor-Specific Antibodies After B... : Transplantation

Background: Donor-specific antibodies (DSA) are considered as reliable biomarkers for antibody-mediated rejection (ABMR) diagnosis.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Obinutuzumab

RT @FarmaOnco: "Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Previously Untreated CLL" Ann Pharm http://t.co/xxhX62CFtu
Gilbert Faure au nom de l'ASSIM's insight:

Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody, with a higher affinity for CD20 epitope, leading to superior cytotoxicity compared with rituximab. The FDA approval was based on a phase III, randomized trial of chlorambucil monotherapy (n = 118), chlorambucil plus obinutuzumab (n = 333), or rituximab (n =330) in previously untreated elderly CLL patients. 

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Stabilisation of ADCs by Lyophilisation | Biopharma

Stabilisation of ADCs by Lyophilisation | Biopharma | Immunology and Biotherapies | Scoop.it
Freeze-drying can be used to stabilise ADCs in order to lengthen shelf life. The molecules are sensitive and product & process need to be developed carefully.
Gilbert Faure au nom de l'ASSIM's insight:

technical aspects of ADC

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Access : Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers : Cancer Gene Therapy

Cancer Gene Therapy is the essential gene therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene therapy for cancer.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Article > World cancer immunotherapy market "to reach $9B in 2022"

Article > World cancer immunotherapy market "to reach $9B in 2022" | Immunology and Biotherapies | Scoop.it
Sales set to grow 23.8% a year (Immuno-oncology market set to reach $9B by 2022 http://t.co/jP4oK20fzG #midkine #oncology #cancer #Immunotherapy #antibody #biotech #pharma)...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Université de Liège, vue côté Recteur
Scoop.it!

ImCyse plans first-in-human-therapy with disease-modifying vaccine to treat multiple sclerosis [sclérose en plaques]

ImCyse plans first-in-human-therapy with disease-modifying vaccine to treat multiple sclerosis [sclérose en plaques] | Immunology and Biotherapies | Scoop.it
Belgian-based ImCyse, a spin-off originally from the Catholic University of Leuven (KUL), but now established at both KUL and University of Liège (ULg), was founded in July 2010 by Prof. Jean-Marie Saint-Remy to valorize discoveries made by his team in […]

Via Bernard Rentier
more...
No comment yet.